Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Northwell Health · Cliniques Universitaires Saint-Luc · +15 more institutions
Indexed incrossrefpubmed
Abstract
Background
In adults with active lupus nephritis, the efficacy and safety of intravenous belimumab as compared with placebo, when added to standard therapy (mycophenolate mofetil or cyclophosphamide-azathioprine), are unknown.
Methods
, and no use of rescue therapy). The time to a renal-related event or death was assessed.
Citation impact
949
total citations
- FWCI
- 89.40
- Percentile
- 100%
- References
- 41
Citations per year
Authors
17- RFRichard FurieCorresponding
Northwell Health, Cliniques Universitaires Saint-Luc, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell
- BHBrad H. Rovin
Cliniques Universitaires Saint-Luc, The Ohio State University
- FHFrédéric Houssiau
Cliniques Universitaires Saint-Luc, UCLouvain
- AMAna Malvar
Cliniques Universitaires Saint-Luc
- YKY K Onno Teng
Cliniques Universitaires Saint-Luc, Leiden University Medical Center
Topics & keywords
Topics
Keywords
- Belimumab
- Lupus nephritis
- Azathioprine
- Medicine
- Cyclophosphamide
- Placebo
- Internal medicine
- Mycophenolate
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.